BAILEE NICHOLE COOK
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant LINCOLN, NE NPI 1942954888
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant NE ABBVIE INC. All categories
General Payments — all program years on this page
$4,192.60
- Category: General Payments
- Program years: PY2022–2024
- Record count: 223
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,423.54 across 69 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,236.70 | 67 |
| Education | $186.84 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $187.73 | 11 |
| Lilly USA, LLC | $136.87 | 4 |
| EISAI INC. | $103.19 | 3 |
| Janssen Biotech, Inc. | $100.78 | 4 |
| SANOFI-AVENTIS U.S. LLC | $89.99 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $87.95 | 4 |
| Acerta Pharma LLC | $57.30 | 3 |
| ARRAY BIOPHARMA INC | $54.98 | 3 |
| Astellas Pharma US Inc | $54.09 | 3 |
| Gilead Sciences, Inc. | $48.15 | 3 |
| Merck Sharp & Dohme Corporation | $44.96 | 3 |
| Celgene Corporation | $44.94 | 3 |
| SERVIER PHARMACEUTICALS LLC | $44.41 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $39.78 | 2 |
| Daiichi Sankyo Inc. | $32.30 | 2 |
| PFIZER INC. | $29.96 | 2 |
| Mirati Therapeutics, Inc. | $26.49 | 1 |
| Novocure Inc. | $24.02 | 2 |
| Genmab U.S., Inc. | $22.09 | 1 |
| SOBI, INC | $18.48 | 1 |
| Genentech USA, Inc. | $17.92 | 1 |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 1 |
| AVEO Pharmaceuticals, Inc. | $17.25 | 1 |
| Karyopharm Therapeutics Inc. | $17.17 | 1 |
| pharmaand GmbH | $16.84 | 1 |
| Ipsen Biopharmaceuticals, Inc | $15.54 | 1 |
| GlaxoSmithKline, LLC. | $15.48 | 1 |
| JAZZ PHARMACEUTICALS INC. | $15.13 | 1 |
| GENZYME CORPORATION | $14.63 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $14.37 | 1 |
| Alexion Pharmaceuticals, Inc. | $13.36 | 1 |
By program year
Records — PY2024 (69)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.